Akso Health Group Beheer

Beheer criteriumcontroles 0/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Linda Wang

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	3.1yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	2.6yrs

Recente managementupdates

Recent updates

CEO

Linda Wang (37 yo)

3.1yrs

Tenure

Ms. Yilin Wang also known as Linda, serves as Chief Executive Officer and Chairwoman of the Board at Akso Health Group (formerly known as Xiaobai Maimai Inc.) since October 18, 2021. She served as Co-Chief...

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Yilin Wang	CEO & Chairwoman of the Board	3.1yrs	geen gegevens	geen gegevens
Stephen P. Brown	Independent Non-Executive Director	2.6yrs	geen gegevens	geen gegevens
Wenjuan Liu	Director	3.3yrs	geen gegevens	geen gegevens
Gerald T. Neal	Independent Non-Executive Director	2.4yrs	geen gegevens	geen gegevens
Zhe Liu	Independent Non-Executive Director	2.1yrs	geen gegevens	geen gegevens

2.6yrs

Gemiddelde duur

39yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van AHG wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.6 jaar), wat duidt op een nieuw bestuur.

Akso Health Group Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Recente managementupdates

Akso Health Group, Annual General Meeting, Apr 30, 2024

Akso Health Group, Annual General Meeting, Jun 19, 2023

Less than half of directors are independent

Less than half of directors are independent

High number of new and inexperienced directors

High number of new and inexperienced directors

Recent updates

Now 21% undervalued

Now 24% undervalued

Full year 2024 earnings released: US$0.19 loss per share (vs US$0.58 loss in FY 2023)

New minor risk - Financial data availability

Akso Health Group, Annual General Meeting, Apr 30, 2024

AHG Announces Plan to Acquire Online Clinic

Akso Health Group announced that it has received $13.974055 million in funding

Akso Health Group Regains Compliance with Nasdaq's Minimum Bid Price Requirement

Full year 2023 earnings released: US$0.58 loss per share (vs US$0.85 loss in FY 2022)

New minor risk - Shareholder dilution

Akso Health Group, Annual General Meeting, Jun 19, 2023

First half 2023 earnings released: EPS: US$0.035 (vs US$0.53 loss in 1H 2022)

Full year 2022 earnings released: US$0.85 loss per share (vs US$1.94 loss in FY 2021)

Less than half of directors are independent

Less than half of directors are independent

Akso Health receives non-compliance notice from Nasdaq

Akso Health Group announced delayed 20-F filing

High number of new and inexperienced directors

High number of new and inexperienced directors

Akso Health Group Announces Board Changes

Akso Health Group Announces Board and Committee Changes

First half 2022 earnings: EPS in line with expectations, revenues disappoint

Akso Health Group(NasdaqGM:AHG) dropped from NASDAQ Composite Index

Xiaobai Maimai Eyes Cancer Treatment As E-Commerce Pivot Sputters

New 90-day high: US$2.78

New 90-day high: US$2.67

Hexindai reports 1H results

Hexindai Inc. to Report First Half, 2021 Results on Dec 21, 2020

Hexindai Inc., Annual General Meeting, Dec 16, 2020

Hexindai Inc. Launches Elite Influencers Program on Xiaobai Maimai

Hexindai Inc. announced delayed 20-F filing

CEO

Tenure

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd